# Chiglitazar Added to Metformin for Type 2 Diabetes

Study · id `cardio:ct-nct04807348` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04807348](<https://clinicaltrials.gov/study/NCT04807348>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04807348

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 533 participants.

## Technical summary

Registry record NCT04807348. Randomized; quadruple masking; primary purpose treatment. Start 2021-07-06 (actual); primary completion 2023-02-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 533 participants (enrolled count; ClinicalTrials.gov record NCT04807348, source copy `cardio:ctgov-nct04807348-2024-07-15`, retrieved 2026-10-26)
- Started: 2021-07-06 (actual) (ClinicalTrials.gov record NCT04807348, source copy `cardio:ctgov-nct04807348-2024-07-15`, retrieved 2026-10-26)
- Primary completion: 2023-02-10 (actual) (ClinicalTrials.gov record NCT04807348, source copy `cardio:ctgov-nct04807348-2024-07-15`, retrieved 2026-10-26)
- Completion: 2023-02-10 (actual) (ClinicalTrials.gov record NCT04807348, source copy `cardio:ctgov-nct04807348-2024-07-15`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04807348, source copy `cardio:ctgov-nct04807348-2024-07-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04807348-2024-07-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Chiglitazar Added to Metformin for Type 2 Diabetes
- Condition: Type 2 Diabetes
- Intervention (Drug): Chiglitazar 32mg
- Intervention (Drug): Chiglitazar 48mg
- Intervention (Drug): Placebo
- Intervention (Drug): Metformin Hydrochloride
- Lead sponsor: Chipscreen Biosciences, Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Chipscreen Biosciences, Ltd. (`cardio:org-chipscreen-biosciences-ltd`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP) (`cardio:pubmed-36654286`)
- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS) (`cardio:pubmed-36654287`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of chiglitazar add-on to metformin in type 2 diabetes mellitus (RECAM study) (`cardio:pubmed-40842343`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 77556d3facd940aceb2c02fe049835b18e543ecc229c3fc5408bd1cd0242e04f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
